Back to results
US 9,926,546 B2Granted
Engineered CRISPR-Cas9 nucleases
AssigneeThe General Hospital Corporation
InventorsJ. Keith Joung, Benjamin Kleinstiver, Vikram Pattanayak
Life of this patent
Estimating the term…
Abstract
Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.
Claims32
An isolated Staphylococcus aureus Cas9 (SaCas9) protein that is at least 95% identical to SEQ ID NO:
- 2, with mutations at one, two, three, four, five, six, or more of the following positions:
- Y211, Y212, W229, Y230, R245, T392, N419, Y651, or R654.
Dependencies are inferred from the claim text.